샘플 요청 목록

 카트 문의
시장보고서
상품코드
1760906

세계의 결핵 검사 시장

Tuberculosis Testing
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 423 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

결핵 검사 세계 시장은 2030년까지 29억 달러에 이를 전망

2024년에 22억 달러로 추정되는 결핵 검사 세계 시장은 2024-2030년간 CAGR 4.9%로 성장하여 2030년에는 29억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 병원은 CAGR 5.3%를 나타내고, 분석 기간 종료시에는 14억 달러에 이를 것으로 예측됩니다. 의사 사무실 부문의 성장률은 분석 기간중 CAGR 4.4%로 추정됩니다.

미국 시장은 1억 3,860만 달러로 추정, 중국은 CAGR5.6%로 성장 예측

미국의 결핵 검사 시장은 2024년에 1억 3,860만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 분석 기간인 2024-2030년 CAGR 5.6%로 성장하여 2030년에는 3억 8,340만 달러 규모에 이를 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 2.7%와 2.8%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 3.6%를 보일 전망입니다.

세계의 결핵 검사 시장 - 주요 동향과 촉진요인 정리

결핵은 여전히 세계 보건의 큰 문제이며, 효과적인 진단과 치료를 위해서는 정확하고 시기적절한 검사가 필수적입니다. 결핵 검사에는 피부 검사, 혈액 검사, 객담 검사, 분자진단 등 다양한 방법이 있습니다. 전통적인 만토우의 투베르쿨린 피부반응검사가 널리 사용되어 왔지만, 인터페론-γ 방출 분석법(IGRA)이나 핵산증폭검사(NAAT)와 같은 더 새롭고 정확한 검사가 개발되어 진단의 정확도가 향상되고 있습니다. 이러한 첨단 검사들은 보다 빠른 결과를 제공하며, 피부 검사에서 위양성을 유발할 수 있는 BCG 백신 접종 전의 영향에 영향을 덜 받습니다.

특히 개발도상국에서는 결핵으로 인한 이환율과 사망률이 높아 결핵 검사의 중요성이 강조되고 있습니다. 결핵을 조기에 정확하게 발견하는 것은 결핵의 확산을 억제하고 적절한 치료를 시작하는 데 매우 중요합니다. 분자진단의 혁신은 약제 내성 균주를 포함한 결핵의 검출 능력을 크게 향상시켜 보다 표적화되고 효과적인 치료 요법을 가능하게 하고 있습니다. 또한, 원격지나 자원이 부족한 환경에서도 신속한 진단과 치료 시작을 가능하게 하는 현장 검사 장비의 보급이 진행되고 있습니다.

결핵 검사 시장의 성장은 몇 가지 요인에 의해 이루어집니다. 특히 결핵 유병률이 높은 국가에서는 결핵 유병률이 증가하고 있어 효과적인 진단 솔루션의 필요성이 증가하고 있습니다. 신속한 자동 검사 플랫폼의 개발 등 분자진단의 기술 발전으로 결핵 검출의 속도와 정확도가 향상되고 있습니다. 다제내성 결핵(MDR-TB) 증가는 내성 패턴을 식별하고 적절한 치료를 유도할 수 있는 고급 진단 검사에 대한 수요를 촉진하고 있습니다. 또한, 세계보건기구(WHO)와 세계 에이즈, 결핵, 말라리아 퇴치 기금(Global Fund to Fight AIDS, Tuberculosis, and Malaria)과 같은 단체의 세계 보건 노력과 자금 지원은 결핵 검사 기술의 개발 및 보급을 지원하고 있습니다. 결핵 검사를 HIV 검진 등 보다 광범위한 공중보건 노력과 통합함으로써 진단 프로그램의 범위와 효과를 강화하여 시장을 더욱 견인하고 있습니다.

부문

검사 유형(배양 기반 검사, 흉부 X-레이, 인터페론-감마 방출 분석(IGRA), 만투 검사(TST), 도말 현미경 검사, 핵산 검사(NAT), 혈청학적 검사, 기타 검사 유형); 최종 용도(병원, 의사 사무실, 참조 실험실, 기타 최종 용도)

조사 대상 기업 예(총 55개사)

  • Akonni Biosystems, Inc.
  • bioMerieux SA
  • Creative Diagnostics
  • CTK Biotech, Inc.
  • DiaSorin SpA
  • Jiangsu Medomics Medical Technology Co., Ltd.
  • NeoGenomics Laboratories, Inc.
  • QIAGEN GmbH
  • Siemens Healthineers AG
  • Takara Bio, Inc.
  • Thermo Fisher Scientific, Inc.
  • ZeptoMetrix LLC

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴에 의해서, 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.07.08

Global Tuberculosis Testing Market to Reach US$2.9 Billion by 2030

The global market for Tuberculosis Testing estimated at US$2.2 Billion in the year 2024, is expected to reach US$2.9 Billion by 2030, growing at a CAGR of 4.9% over the analysis period 2024-2030. Hospitals, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Physicians Office segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$138.6 Million While China is Forecast to Grow at 5.6% CAGR

The Tuberculosis Testing market in the U.S. is estimated at US$138.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$383.4 Million by the year 2030 trailing a CAGR of 5.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Tuberculosis Testing Market - Key Trends & Drivers Summarized

Tuberculosis (TB) remains a major global health challenge, and accurate, timely testing is crucial for effective diagnosis and treatment. Tuberculosis testing involves various methods, including skin tests, blood tests, sputum tests, and molecular diagnostics. The traditional Mantoux tuberculin skin test has been widely used, but newer, more accurate tests like the interferon-gamma release assays (IGRAs) and nucleic acid amplification tests (NAATs) have been developed to improve diagnostic accuracy. These advanced tests provide quicker results and are less affected by prior BCG vaccination, which can cause false positives in skin tests.

The importance of tuberculosis testing is underscored by the high morbidity and mortality rates associated with the disease, particularly in developing countries. Early and accurate detection is critical to controlling the spread of TB and initiating appropriate treatment. Innovations in molecular diagnostics have significantly enhanced the ability to detect TB, including drug-resistant strains, enabling more targeted and effective treatment regimens. Point-of-care testing devices are also becoming more prevalent, allowing for faster diagnosis and treatment initiation in remote and resource-limited settings.

The growth in the tuberculosis testing market is driven by several factors. The increasing prevalence of TB, particularly in high-burden countries, has heightened the need for effective diagnostic solutions. Technological advancements in molecular diagnostics, such as the development of rapid, automated testing platforms, have improved the speed and accuracy of TB detection. The growing incidence of multidrug-resistant TB (MDR-TB) has also spurred the demand for advanced diagnostic tests that can identify resistance patterns and guide appropriate treatment. Additionally, global health initiatives and funding from organizations such as the WHO and the Global Fund to Fight AIDS, Tuberculosis, and Malaria are supporting the development and deployment of TB testing technologies. The integration of TB testing with broader public health efforts, such as HIV screening, further drives the market by enhancing the reach and impact of diagnostic programs.

SCOPE OF STUDY:

The report analyzes the Tuberculosis Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Test Type (Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests, Other Test Types); End-Use (Hospitals, Physicians Office, Reference Laboratories, Other End-Uses)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Select Competitors (Total 55 Featured) -

  • Akonni Biosystems, Inc.
  • bioMerieux SA
  • Creative Diagnostics
  • CTK Biotech, Inc.
  • DiaSorin SpA
  • Jiangsu Medomics Medical Technology Co., Ltd.
  • NeoGenomics Laboratories, Inc.
  • QIAGEN GmbH
  • Siemens Healthineers AG
  • Takara Bio, Inc.
  • Thermo Fisher Scientific, Inc.
  • ZeptoMetrix LLC

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Tariff Impact on Global Supply Chain Patterns
    • Tuberculosis Testing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • Global Market Overview and Outlook
    • Global Tuberculosis Testing Market Exuding High Degree of Vim & Vigor
    • North America Claims Commanding Revenue Share
    • Culture-based Tests & Hospitals: Primary Contributors to Tuberculosis Testing Market
    • Salient Factors Influencing Dynamism of Global Tuberculosis Testing Market
    • Intense Competition Drive Players to Bet on Innovations
    • Molecular Diagnosis Innovations Soaking Up Limelight in the Tuberculosis Testing Arena
    • W.H.O Aims to Improve Access to Rapid Molecular Tests for Diagnosis of TB & Drug-Resistant TB
    • WHO-Endorsed Molecular Platforms & Tests
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Global Tuberculosis Efforts to Drive the Market for Tuberculosis Testing
    • Bracing Technological Innovations, Tuberculosis Testing Moves in New Direction
    • Tuberculosis Screening: The Dawn of Artificial Intelligence Technology
    • Nanodiagnostics Set to Witness Growth in TB Testing
    • A Nanobiosensor for Rapid Detection of Mycobacterium Tuberculosis
    • CRISPR-based Biosensing to See Significant Growth in Pediatric Tuberculosis
    • Present Limitations and Future Directions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Culture-Based Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Culture-Based Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Culture-Based Tests by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Chest X-Ray by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Chest X-Ray by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Chest X-Ray by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Interferon-Gamma Release Assay (IGRA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Interferon-Gamma Release Assay (IGRA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Interferon-Gamma Release Assay (IGRA) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Mantoux Test (TST) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Mantoux Test (TST) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Mantoux Test (TST) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Smear Microscopy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Smear Microscopy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Smear Microscopy by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Nucleic Acid Testing (NAT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Nucleic Acid Testing (NAT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Nucleic Acid Testing (NAT) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Serological Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Serological Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 21: World 15-Year Perspective for Serological Tests by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 24: World 15-Year Perspective for Other Test Types by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 27: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Physicians Office by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Physicians Office by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 30: World 15-Year Perspective for Physicians Office by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Reference Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Reference Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 33: World 15-Year Perspective for Reference Laboratories by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 36: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 37: World Tuberculosis Testing Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Tuberculosis Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Tuberculosis Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Tuberculosis Testing by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Tuberculosis Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Tuberculosis Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Tuberculosis Testing by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • FRANCE
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: France 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Germany Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Germany 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 83: Germany Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Germany 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Italy Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Italy 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 89: Italy Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Italy Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Italy 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 92: UK Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: UK Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: UK 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 95: UK Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: UK Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: UK 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 98: Spain Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Spain Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Spain 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 101: Spain Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Spain Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Spain 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 104: Russia Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Russia Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Russia 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 107: Russia Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Russia Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Russia 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Europe Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Rest of Europe 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Rest of Europe Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Rest of Europe 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Asia-Pacific 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Asia-Pacific Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Asia-Pacific 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific Historic Review for Tuberculosis Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Asia-Pacific 15-Year Perspective for Tuberculosis Testing by Geographic Region - Percentage Breakdown of Value Revenues for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • AUSTRALIA
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 125: Australia Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Australia Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Australia 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 128: Australia Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Australia Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Australia 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 131: India Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: India Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: India 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 134: India Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: India Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: India 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 137: South Korea Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: South Korea Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: South Korea 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 140: South Korea Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: South Korea Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: South Korea 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 143: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Asia-Pacific Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Asia-Pacific 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Asia-Pacific Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Asia-Pacific 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 149: Latin America Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Latin America Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Latin America 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 152: Latin America Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Latin America Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Latin America 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 155: Latin America Recent Past, Current & Future Analysis for Tuberculosis Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 156: Latin America Historic Review for Tuberculosis Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Latin America 15-Year Perspective for Tuberculosis Testing by Geographic Region - Percentage Breakdown of Value Revenues for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 158: Argentina Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Argentina Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Argentina 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 161: Argentina Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Argentina Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Argentina 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 164: Brazil Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Brazil Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Brazil 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 167: Brazil Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Brazil Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Brazil 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 170: Mexico Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Mexico Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Mexico 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 173: Mexico Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Mexico Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Mexico 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 176: Rest of Latin America Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Latin America Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Latin America 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 179: Rest of Latin America Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Latin America Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Latin America 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 182: Middle East Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Middle East Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Middle East 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 185: Middle East Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Middle East Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Middle East 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 188: Middle East Recent Past, Current & Future Analysis for Tuberculosis Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 189: Middle East Historic Review for Tuberculosis Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Middle East 15-Year Perspective for Tuberculosis Testing by Geographic Region - Percentage Breakdown of Value Revenues for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • IRAN
    • TABLE 191: Iran Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Iran Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Iran 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 194: Iran Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Iran Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Iran 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 197: Israel Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Israel Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Israel 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 200: Israel Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Israel Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Israel 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 203: Saudi Arabia Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Saudi Arabia Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Saudi Arabia 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 206: Saudi Arabia Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Saudi Arabia Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Saudi Arabia 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 209: UAE Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: UAE Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: UAE 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 212: UAE Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: UAE Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: UAE 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 215: Rest of Middle East Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Rest of Middle East Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Rest of Middle East 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 218: Rest of Middle East Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Rest of Middle East Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Rest of Middle East 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 221: Africa Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Africa Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Africa 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 224: Africa Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Africa Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Africa 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제